MétaCan
Menu
Back to cohort
Record W4229013347 · doi:10.1182/blood.2021014956

Lenalidomide promotes the development of <i>TP53</i>-mutated therapy-related myeloid neoplasms

2022· article· en· W4229013347 on OpenAlexaff
Adam S. Sperling, Veronica Guerra, James A. Kennedy, Yuanqing Yan, Joanne I. Hsu, Feng Wang, Andrew Nguyen, Peter G. Miller, Marie McConkey, Vanessa A. Quevedo Barrios, Ken Furudate, Linda Zhang, Rashmi Kanagal‐Shamanna, Jianhua Zhang, Latasha Little, Curtis Gumbs, Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Farhad Ravandi, Hagop M. Kantarjian, Guillermo Garcia‐Manero, P. Andrew Futreal, Benjamin L. Ebert, Koichi Takahashi

Bibliographic record

VenueBlood · 2022
Typearticle
Languageen
FieldMedicine
TopicAcute Myeloid Leukemia Research
Canadian institutionsPrincess Margaret Cancer CentreUniversity of TorontoHealth Sciences CentreUniversity Health NetworkSunnybrook Health Science Centre
FundersNational Cancer InstituteUniversity of Texas MD Anderson Cancer CenterNational Heart, Lung, and Blood InstituteNational Institutes of HealthAndrew Sabin Family FoundationEdward P. Evans FoundationHoward Hughes Medical InstituteCancer Prevention and Research Institute of TexasDr. Miriam and Sheldon G. Adelson Medical Research FoundationWelch FoundationUniversity of Texas SystemLeukemia and Lymphoma Society
KeywordsLenalidomideProgenitor cellHaematopoiesisThalidomideMyeloidCancer researchBiologyPomalidomideStem cellImmunologyMultiple myelomaGenetics

Abstract

fetched live from OpenAlex

There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with driver gene mutations arise in the background of clonal hematopoiesis (CH) under the positive selective pressure of chemo- and radiation therapies. Uncovering the exposure relationships that provide selective advantage to specific CH mutations is critical to understanding the pathogenesis and etiology of t-MNs. In a systematic analysis of 416 patients with t-MN and detailed prior exposure history, we found that TP53 mutations were significantly associated with prior treatment with thalidomide analogs, specifically lenalidomide. We demonstrated experimentally that lenalidomide treatment provides a selective advantage to Trp53-mutant hematopoietic stem and progenitor cells (HSPCs) in vitro and in vivo, the effect of which was specific to Trp53-mutant HSPCs and was not observed in HSPCs with other CH mutations. Because of the differences in CK1α degradation, pomalidomide treatment did not provide an equivalent level of selective advantage to Trp53-mutant HSPCs, providing a biological rationale for its use in patients at high risk for t-MN. These findings highlight the role of lenalidomide treatment in promoting TP53-mutated t-MNs and offer a potential alternative strategy to mitigate the risk of t-MN development.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.038
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.266
Teacher spread0.245 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations139
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueBloodSame topicAcute Myeloid Leukemia ResearchFrench-language works237,207